Synergy Pharmaceuticals June 15th Short Interest Update

Synergy Pharmaceuticals (NASDAQ:SGYP) has seen a rise of 1,554,999 shares or 8.7% in the short interest. The remaining shorts are 11.4% of the total floated shares. The net short interest, as on June 15,2016, stood at 19,521,856 shares and the stocks days to cover will be 6 by factoring in the average per day volume of 3,419,896 shares. On May 31,2016, 17,966,857 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Synergy Pharmaceuticals (NASDAQ:SGYP): The stock opened at $3.53 on Friday but the bulls could not build on the opening and the stock topped out at $3.70 for the day. The stock traded down to $3.53 during the day, due to lack of any buying support eventually closed down at $3.67 with a loss of -3.42% for the day. The stock had closed at $3.80 on the previous day. The total traded volume was 11,046,626 shares.

The company shares have dropped -53.19% from its 1 Year high price. On Jul 7, 2015, the shares registered one year high at $10.15 and the one year low was seen on Mar 23, 2016. The 50-Day Moving Average price is $3.49 and the 200 Day Moving Average price is recorded at $3.79.

Synergy Pharmaceuticals (NASDAQ:SGYP) has climbed 0.55% in the past week and advanced 1.94% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.22% and the outperformance has advanced to 5.03% for the last 4 weeks period.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.